The tripartite symbiosis between legumes, rhizobia and mycorrhizal fungi are generally considered to be beneficial for the nitrogen (N) uptake of legumes, but the facilitation of symbiosis in legume/non-legume intercropping systems is not clear. Therefore, the aims of the research are as follows: (1) to verify if the dual inoculation can facilitate the N uptake and N transfer in maize/soybean intercropping systems and (2) to calculate how much N will be transferred from soybean to maize. A pot experiment with different root separations [solid barrier, mesh (30 μm) barrier and no barrier] was conducted, and the 15N isotopic tracing method was used to calculate how much N transferred from soybean to maize inoculated with arbuscular mycorrhizal fungi (AMF) and rhizobium in a soybean (Glycine max L.cv. Dongnong No. 42)/maize (Zea mays L.cv. Dongnong No. 48) intercropping system. Compared with the Glomus mosseae inoculation (G.m.), Rhizobium SH212 inoculation (SH212), no inoculation (NI), the dual inoculation (SH212+G.m.) increased the N uptake of soybean by 28.69, 39.58, and 93.07% in a solid barrier system. N uptake of maize inoculated with both G. mosseae and rhizobium was 1.20, 1.28, and 1.68 times more than that of G.m., SH212 and NI, respectively, in solid barrier treatments. In addition, the amount of N transferred from soybean to maize in a dual inoculation system with a mesh barrier was 7.25, 7.01, and 11.45 mg more than that of G.m., SH212 and NI and similarly, 6.40, 7.58, and 12.46 mg increased in no barrier treatments. Inoculating with both AMF and rhizobium in the soybean/maize intercropping system improved the N fixation efficiency of soybean and promoted N transfer from soybean to maize, resulting in the improvement of yield advantages of legume/non-legume intercropping.

Purpose: To investigate the morphological feature, visual acuity, and prevalence of macular complications in highly myopic eyes with different categories of myopic maculopathy (MM) according to the META-PM classification system. Methods: The clinical records of 1,132 consecutive patients (1,841 eyes) with high myopia (refractive error ≤ −6D and axial length ≥26.5 mm), who visited the High Myopia Clinic at the Zhongshan Ophthalmic Center from January 2014 to July 2017, were reviewed. Fundus photograph, optical coherence tomography, axial length, refractive error, and best-corrected visual acuity were measured in each patient. Myopic maculopathy was graded from fundus photographs according to the META-PM classification, including tessellated fundus (C1), diffuse chorioretinal atrophy (C2), patchy atrophy (C3), and macular atrophy (C4). Other macular complications, including foveoschisis, extrafoveal schisis, full-thickness macular hole, epiretinal membrane, lacquer cracks, Fuchs spot, choroidal neovascularization, macular hemorrhage, and dome-shaped macula, were also investigated. Results: Among the 1,841 eyes, 58 (3.15%) had no MM (C0), 779 (42.31%) had tessellated fundus only (C1), 524 (28.46%) had diffuse chorioretinal atrophy (C2), 352 (19.12%) had patchy chorioretinal atrophy (C3), and 128 (6.95%) had macular atrophy (C4). Age increased and best-corrected visual acuity became worse with the severity of MM (P < 0.01). Axial length was significantly longer with the severity of MM from C0 to C3 (P < 0.01), and spherical equivalent was greater with the severity of MM from C0 to C3 (P < 0.01) but was not different between C3 and C4 (P > 0.05). Subfoveal and parafoveal choroidal thicknesses were significantly thinner from C0 to C3 (P < 0.01). However, no significant difference was found between C3 and C4 in parafoveal choroidal thickness (P > 0.05). The complications were different among C0 to C4 correlated with MM (P < 0.01). The complications of foveoschisis, choroidal neovascularization, hemorrhage, lacquer cracks, Fuchs spot, dome-shaped macula, and epiretinal membrane were different between C1 and C2 (P < 0.01), but none of the complications were different between C3 and C4 (P > 0.05) except Fuchs spot (P = 0.009). Conclusion: The morphological and functional characteristics in eyes with high myopia were positively correlated with the severity of C0 to C3 MM. However, no morphological difference was found between C3 and C4. The absence of the progressive relationship between C3 and C4 might be determined.

Leaves of Ampelopsis grossedentata have been consumed in southern China as health tea and herbal medicine. In this study, two kinds of flavonoid‐rich extracts from leaves of A. grossedentata were prepared by traditional solvent extraction (product A) and recrystallization (product B). By analysis of ultraviolet‐visible (UV) spectrometry, infrared (IR) spectrometry, electrospray ionization mass spectrometry (ESI‐MS), nuclear magnetic resonance (NMR) spectrometry and high‐performance liquid chromatography (HPLC)‐ESI/MS, the major flavonoid in two products was identified as (+)‐dihydromyricetin (DMY). Also, by HPLC, the contents of DMY in leaves, product A and product B were measured to be 32.96 ± 1.18%, 77.15 ± 1.98% and 95.12 ± 2.86%, respectively. Various antioxidant tests (1,1‐diphenyl‐2‐picrylhydrazyl radical scavenging, reducing power, antioxidant activity in linoleic acid system) showed that the antioxidant activity of the flavonoid‐rich extracts could be comparable with that of tertiary butylhydroquinone. The flavonoid‐rich extracts from A. grossedentata leaves have a promise to be a new natural antioxidant with potential application in food industry. PRACTICAL APPLICATION Leaves of Ampelopsis grossedentata are consumed in southern China as health tea (Tengcha) and herbal medicine. In this study, the flavonoid‐rich extracts from leaves of A. grossedentata, which were rich in (+)‐dihydromyricetin, were prepared by traditional solvent extraction and recrystallization. Also, the antioxidant activity of the extracts can be comparable with that of tertiary butylhydroquinone. The results obtained in this study suggest that leaves of A. grossedentata may have potential as a new source of natural antioxidant and health food with great commercial interest in the food and phytopharmaceutical market.

No abstract

PurposeTo evaluate the prevalence of dome-shaped macula (DSM) in highly myopic eyes among Chinese Han and to detect the correlation with myopic maculopathy and macular complications.MethodsA total of 736 Chinese Han patients (1384 eyes) with high myopia (refractive error≤6.0 diopters or axial length ≥26.5 mm) are reviewed based on information entered into a high-myopia database at Zhongshan Ophthalmic Centre. Subfoveal choroidal thickness (SFCT) and parafoveal choroidal thickness (PFCT) are measured. The prevalence of DSM in patients with myopic maculopathy is categorised from C0 to C4. Clinical features, including macular complications, SFCT and PFCT, are compared between myopic eyes with and without DSM.ResultsAmong the 1384 eyes, 149 (10.77%) show DSM. In highly myopic eyes without macular complications, the best corrected visual acuity is significantly worse in patients with DSM (p=0.002), and the ratio between subfoveal and parafoveal choroidal thickness (S/PCT) is significantly elevated in patients with DSM (p=0.021). The proportion of foveal schisis (17.24% vs 62.86%) is much lower in eyes with DSM compared with those without DSM. However, the proportions of extrafoveal schisis (39.66% vs 5.37%), foveal serous retinal detachment (SRD) (5.17% vs 0) and epiretinal membrane (ERM) (24.14% vs 10.74%) are much higher in eyes with DSM. The proportion of DSM was lower in C0 and C1, but higher proportion of DSM was found in C3 and C4.ConclusionsDSM is found in 10.77% of highly myopic eyes among Chinese Han. DSM might be a protective mechanism for foveal schisis and a risk factor for extrafoveal schisis, SRD and ERM.

No abstract

PURPOSE. To evaluate the microstructure of the fovea in patients with familial exudative vitreoretinopathy (FEVR) compared to healthy controls using optical coherence tomography angiography (OCTA). METHODS. In this consecutive, cross-sectional, observational case series, 41 eyes of 41 patients diagnosed as FEVR and 37 eyes in 37 control subjects were studied. OCTA was utilized to automatically measure the foveal avascular zone (FAZ) and the vessel density (VD). Inner retinal thicknesses (IRT) and central retinal thickness (CRT) were measured with the instrument caliper. Targeted next-generation sequencing was performed, and phenotypegenotype association was analyzed. RESULTS. Small FAZ was found in 31.70% (13/41) FEVR eyes but not in controls. Greater CRT and lower superficial foveal VD were noted in FEVR patients. FAZ is negatively correlated with IRT. Persistence of the inner retinal layer (IRL) in fovea was present in 48.78% (20/41) FEVR eyes but not found in controls. Zero percent (0/10) of patients with the low-density lipoprotein receptor-related protein 5 (LRP5) mutation, 50% (1/2) with the frizzled-4 (FZD4) mutation, and 66.67% (3/4) with the tetraspanin-12 (TSPAN12) mutation had preserved foveal IRL and small FAZ. CONCLUSIONS. Our data indicate FEVR status is associated with a significantly smaller FAZ, decreased vascular density in both the superficial and deep layers of parafoveal area, a thicker fovea, and an abnormally preserved IRL in fovea. In addition, patients with the LRP5 mutation had a milder phenotype than those with the FDZ4 or TSPAN12 mutations. These novel findings could provide insight into the understanding of the pathogenesis of FEVR.

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of sacubitril/valsartan in HF. In this review, we first introduced the pharmacological mechanisms of sacubitril/valsartan, including the reduction in the degradation of natriuretic peptides in the natriuretic peptide system and inhibition of the renin-angiotensin system. Then, we summarized the efficacy of sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) including the reduction in risks of mortality and hospitalization, reversal of cardiac remodeling, regulation of biomarkers of HF, improvement of the quality of life, antiarrhythmia, improving renal dysfunction and regulation of metabolism. Finally, we discussed the safety and tolerability of sacubitril/valsartan in the treatment of HFrEF or HFpEF. Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high. In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients. Sacubitril/valsartan will probably be a promising anti-HF drug in the near future.